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Allogeneic hematopoietic stem cell transplantation (allo-
HSCT) is the only curative treatment for MDS. GVHD is one of
the main causes of NRM in unmodiﬁed allo-HSCT. We aimed
to study causes of NRM after TCD transplant.
108 patients with MDS underwent TCD allo-HSCT at MSKCC
between 1/2001- 4/2012. Median age was 57.6 (18.1-73.0).
WHO subtypes at diagnosis were: RA/RCMD 30, RAEB-I 34 &
RAEB-II 44. In 73 pts disease progressed prior to transplant.
101 pts were treated before transplant (hypomethylating
agents 27, induction chemotherapy 73, syngeneic transplant
1). All pts underwent conditioning with a myeloablative
regimen and received ATG to prevent graft rejection (other
than 4 pts). Hematopoietic stem cells source was PB in 102
pts and BM in 6 pts. BM grafts were depleted of T-cells by
soybean agglutinin followed by sheep RBC rosetting, and PB
graft by immunomagnetic CD34+ selection (Isolex initially
and CliniMACS after 09/2011). Donors were HLA matched
(79; 39 related and 40 unrelated) or mismatched (29).
The OS (with 95% conﬁdence interval) at 1 year was 70.2%
(60.5-77.9) and at 3 years 50.0 % (39.9-59.2). Cumulative
incidence (CI) at 1 year of grade III-IV acute GvHD was 12.1%
(6.8-19.1) and of chronic GvHD 2.8% (0.8-7.4). CI of relapse at
1 year was 11.2 % (6.1-18.0) and at 2 years 16.0% (9.7-23.6).
106 patients engrafted (2 died early and were not evaluable).
The CI of NRM at 1 year was 23.3% (15.8-31.7) and at 2 years
31.8 % (23.2-40.7). The causes of death were deﬁned ac-
cording to Copelan’s criteria (BBMT 2007). Infections
accounted for 51% of NRM; 32% bacterial, 16% viral and 3%
fungal. In a univariate landmark analysis, the only factorassociated with increased NRM was a low CD4 at 3 months
(p¼0.012). For patients with CD4<100 vs 100 at 3 months
post transplant, the 1 year NRM was 21.9% (9.5-37.5) vs 8.6%
(2.1-20.8) and at 3 years 35.4% (18.9-52.3) vs 8.6% (2.1-20.8).
The CI of death due to infection was signiﬁcantly higher in
patients with CD4<100 vs 100 (p¼0.019): 15.2% (5.4-29.5)
vs 2.9% (0.2-12.9) at 1 year and 21.3% (9.2-36.8) vs 2.9% (0.2-
12.9) at 3 years. There was a trend for higher NRM in older
patients (>50) (p¼0.094), with estimated incidence of 34.9%
vs 20.8% at two years. The following factors were not asso-
ciated with an increased NRM: etiology (de-novo vs therapy
related), conditioning regimen (chemotherapy vs TBI), pre-
transplant therapy (hypomethylating vs induction chemo-
therapy), donor (MRD vs MUD vs MM donor and mixed T cell
chimerism (<50% donor chimerism) on day 100 post trans-
plant and BM chimerism at 6 months (<95% donor
chimerism).
Infections were the main cause for NRM followed by GVHD.
Low CD4 count at 3 months post transplant was a strong
predictor for NRM and in particular for infection related
mortality. TCD allo-HSCT associated with low incidence of
GvHD can serve as a platform to enhance immunity against
speciﬁc common infections etiologies with viral or fungal
speciﬁc cytotoxic T cells.
